Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $51.2200 (17.1%) ($51.2200 - $51.2200) on Tue. Dec. 15, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.26% (three month average) | RSI | 81 | Latest Price | $51.2200(17.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 11.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 23.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(60%) ARKK(56%) IBB(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -3.13% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-1%) UNG(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.13% (StdDev 6.26%) | Hourly BBV | 1.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $41.71(22.8%) | 10 Day Moving Average | $35.53(44.16%) | 20 Day Moving Average | $32.6(57.12%) | To recent high | 0% | To recent low | 115.9% | Market Cap | $6.487b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |